Search
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesEliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesNabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalTetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction … This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsProducts: Ran-nabiloneVadadustat
go.drugbank.com/drugs/DB12255ApprovedInvestigational[A244165] Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to [darbepoetin alfa] for the treatment of anemia in patients with CKD undergoing dialysis … [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersPalladium Pd-103
go.drugbank.com/drugs/DB15016ExperimentalPalladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).
Deferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 InhibitorsTolmetin
go.drugbank.com/drugs/DB00500ApprovedA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Synonyms: 1-Methyl-5-p-toluoylpyrrole-2-acetic acid, 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acidInternational brands: Tolectin DSBRG01
go.drugbank.com/drugs/DB18173InvestigationalBRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]
Boric acid
go.drugbank.com/drugs/DB11326ApprovedInvestigationalBoric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and
Mixtures: Recal D, Trimo San Deodorant Vaginal JellyVidPrevtyn Beta
go.drugbank.com/drugs/DB16427ApprovedVidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur. … [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from